Profile data is unavailable for this security.
About the company
Galectin Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company's lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the United States Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
- Revenue in USD (TTM)0.00
- Net income in USD-45.23m
- Incorporated2001
- Employees14.00
- LocationGalectin Therapeutics IncSUITE 2404960 PEACHTREE INDUSTRIAL BOULEVARDNORCROSS 30071United StatesUSA
- Phone+1 (678) 620-3186
- Fax+1 (770) 864-1327
- Websitehttps://galectintherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Checkpoint Therapeutics Inc | 47.00k | -46.47m | 165.05m | 23.00 | -- | -- | -- | 3,511.78 | -1.44 | -1.44 | 0.0013 | -0.2749 | 0.0127 | -- | -- | 2,043.48 | -1,256.40 | -142.43 | -- | -342.79 | -- | -- | -98,868.09 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
| Actuate Therapeutics Inc | -100.00bn | -100.00bn | 167.58m | 11.00 | -- | 31.27 | -- | -- | -- | -- | -- | 0.2744 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0703 | -- | -- | -- | -22.74 | -- | -- | -- |
| Verastem Inc | 10.00m | -93.45m | 168.68m | 73.00 | -- | 13.80 | -- | 16.87 | -3.18 | -3.18 | 0.3311 | 0.8002 | 0.0661 | -- | 100.00 | 136,986.30 | -61.78 | -62.70 | -77.44 | -75.18 | -- | -- | -934.54 | -406.17 | -- | -- | 0.5579 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
| Greenwich Lifesciences Inc | 0.00 | -10.50m | 168.91m | 3.00 | -- | 33.90 | -- | -- | -0.8111 | -0.8111 | 0.00 | 0.3791 | 0.00 | -- | -- | 0.00 | -140.17 | -36.43 | -151.72 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
| Heron Therapeutics Inc | 137.74m | -27.97m | 169.87m | 126.00 | -- | -- | -- | 1.23 | -0.1841 | -0.1841 | 0.9067 | -0.2637 | 0.6122 | 0.871 | 2.11 | 1,093,151.00 | -12.43 | -53.55 | -19.65 | -71.24 | 72.19 | 52.52 | -20.30 | -170.12 | 1.74 | -- | 1.36 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Adaptimmune Therapeutics PLC - ADR | 175.04m | -44.52m | 169.99m | 449.00 | -- | 2.12 | -- | 0.9712 | -0.2126 | -0.2126 | 0.7109 | 0.3128 | 0.5701 | -- | 26.34 | 389,846.30 | -14.50 | -41.19 | -18.73 | -48.21 | -- | -- | -25.43 | -714.26 | 3.82 | -- | 0.384 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| DiaMedica Therapeutics Inc | 0.00 | -21.71m | 171.85m | 18.00 | -- | 3.58 | -- | -- | -0.5527 | -0.5527 | 0.00 | 1.12 | 0.00 | -- | -- | 0.00 | -39.23 | -45.38 | -41.66 | -48.24 | -- | -- | -- | -- | -- | -- | 0.0055 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
| Galectin Therapeutics Inc | 0.00 | -45.23m | 175.31m | 14.00 | -- | -- | -- | -- | -0.7284 | -0.7284 | 0.00 | -1.48 | 0.00 | -- | -- | 0.00 | -176.31 | -92.08 | -587.13 | -121.97 | -- | -- | -- | -- | -- | -7.18 | 8.66 | -- | -- | -- | -15.26 | -- | -- | -- |
| Tenaya Therapeutics Inc | 0.00 | -117.23m | 175.87m | 140.00 | -- | 1.56 | -- | -- | -1.44 | -1.44 | 0.00 | 1.42 | 0.00 | -- | -- | 0.00 | -70.20 | -- | -78.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Nkarta Inc | 0.00 | -110.61m | 176.42m | 159.00 | -- | 0.4095 | -- | -- | -1.87 | -1.87 | 0.00 | 6.11 | 0.00 | -- | -- | 0.00 | -23.59 | -32.39 | -24.86 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Caribou Biosciences Inc | 11.48m | -148.12m | 177.48m | 158.00 | -- | 0.6312 | -- | 15.47 | -1.65 | -1.65 | 0.128 | 3.11 | 0.0286 | -- | 5.08 | 72,626.59 | -36.94 | -- | -39.76 | -- | -- | -- | -1,290.81 | -- | -- | -1,321.46 | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| Kyverna Therapeutics Inc | 0.00 | -110.66m | 177.77m | 119.00 | -- | 0.5875 | -- | -- | -2.50 | -2.50 | 0.00 | 7.01 | 0.00 | -- | -- | 0.00 | -51.27 | -- | -57.66 | -- | -- | -- | -- | -- | -- | -- | 0.0038 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
| Inozyme Pharma Inc | 0.00 | -96.49m | 179.23m | 59.00 | -- | 2.16 | -- | -- | -1.55 | -1.55 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -55.29 | -45.00 | -60.60 | -48.90 | -- | -- | -- | -- | -- | -- | 0.3554 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Nektar Therapeutics | 93.14m | -168.30m | 184.46m | 137.00 | -- | 3.77 | -- | 1.98 | -0.8371 | -0.8371 | 0.4634 | 0.265 | 0.2483 | 3.96 | 84.52 | 679,832.10 | -44.87 | -31.02 | -53.39 | -34.63 | 67.80 | 78.04 | -180.70 | -372.21 | 4.24 | -15.53 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| Fulcrum Therapeutics Inc | 80.87m | -17.91m | 186.58m | 76.00 | -- | 0.6268 | -- | 2.31 | -0.3098 | -0.3098 | 1.29 | 4.77 | 0.2899 | -- | 23.41 | 1,064,092.00 | -6.42 | -50.55 | -6.77 | -55.91 | -- | -- | -22.15 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
Data as of Nov 21 2024. Currency figures normalised to Galectin Therapeutics Inc's reporting currency: US Dollar USD
12.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.09m | 3.36% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 1.50m | 2.41% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Sep 2024 | 1.18m | 1.90% |
| Geode Capital Management LLCas of 30 Sep 2024 | 862.54k | 1.39% |
| Commonwealth Equity Services LLCas of 30 Sep 2024 | 483.26k | 0.78% |
| Wealthspire Advisors LLCas of 30 Sep 2024 | 398.37k | 0.64% |
| Geneos Wealth Management, Inc.as of 30 Sep 2024 | 352.94k | 0.57% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 251.01k | 0.40% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 234.28k | 0.38% |
| Western International Securities, Inc.as of 30 Sep 2024 | 207.10k | 0.33% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
